MedTrace Logo

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

NCT00833599 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 283

Last updated 2026-03-10

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the feasibility of near-infrared fluorescence imaging in subjects with acquired or hereditary lymphedema, in subjects with lipidema and other lymphovascular disorders and in normal health subjects; in order to attempt to correlate imaging phenotype(s) with genotype(s).

Conditions

  • Lymphedema
  • Lymphatic Disorders
  • Lipedema
  • Vascular Malformation
  • Vascular Anomaly
  • Dercum Disease

Interventions

DRUG

NIRFLI with ICG

We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Lymphatic Malformation Institute

    collaborator OTHER

  • Lipedema Foundation

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Eva M Sevick, PhD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2030-12-01
Completion
2030-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833599 on ClinicalTrials.gov